Abstract:Background: Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that symmetrically di-methylates arginine residues on both histone and non-histone protein substrates. Accumulating evidence suggests that PRMT5 exerts its oncogenic properties in a wide spectrum of human malignancies. However, the underlying mechanisms by which PRMT5 contributes to the progression of colorectal cancer (CRC) remain to be defined.Methods: Western blot and real-time PCR were used to analyze the expression of CDKN2B. Co-immunoprecipitation (Co-IP), immunofluorescence and GST pulldown assays were employed to investigate the interaction between PRMT5 and EZH2. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to validate CDKN2B as a direct target of PRMT5/EZH2. DNA methylation status at the CpG islands of promoter region of CDKN2B gene was analyzed by bisulfite sequencing. The effect of PRMT5/EZH2 on malignant phenotypes was examined through in vitro and in vivo assays. PRMT5 and EZH2 protein expression levels in CRC tissues were analyzed by immunohistochemistry (IHC) staining.Results: We observed that PRMT5-deficient CRC cells exhibit proliferation defects in vitro. PRMT5 was identified as a major transcriptional repressor of CDKN2B (p15INK4b) for determining CRC progression. Mechanistically, PRMT5-mediated histone marks H4R3me2s and H3R8me2s were predominantly deposited at the promoter region of CDKN2B gene in CRC cells. Knockdown of PRMT5 in CRC cells decreased the accumulation of H4R3me2s and H3R8me2s marks and reduced the CpG methylation level of CDKN2B promoter, then re-activated CDKN2B expression. Strikingly, silencing of CDKN2B partially abrogated the proliferation defects caused by PRMT5 depletion in vitro and in vivo. Furthermore, we proved that PRMT5 interacted with Enhancer of zeste homolog 2 (EZH2), leading to enhanced EZH2 binding and H3K27me3 deposition together with decreased transcriptional output of CDKN2B gene. Importantly, we found that the combined interventions exerted a synergistic inhibitory effect of combined treatment with PRMT5i (GSK591) and EZH2i (GSK126) on the growth of CRC cells/xenografts in vitro and in vivo. Moreover, PRMT5 and EZH2 were found to be significantly elevated and associated with poor prognosis in CRC patients.Conclusion: PRMT5 functionally associates with EZH2 to promote CRC progression through epigenetically repressing CDKN2B expression. Thus, our findings raise the possibility that combinational intervention of PRMT5 and EZH2 may be a promising strategy for CRC therapy.

Prdm5 suppresses ApcMin-driven intestinal adenomas and regulates monoacylglycerol lipase expression

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

APC Promoter Methylation in Gastrointestinal Cancer

PRDM3 Attenuates Pancreatitis and Pancreatic Tumorigenesis by Regulating Inflammatory Response

Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis

Promoter Methylation-Mediated Downregulation of PRDM5 Contributes to the Development of Lung Squamous Cell Carcinoma.

Prmt5 Deficient Mouse B Cells Display RNA Processing Complexity and Slower Colorectal Tumor Progression.

Silencing of PRDM5 Increases Cell Proliferation and Inhibits Cell Apoptosis in Glioma

Malic Enzyme 1 (ME1) is pro-oncogenic in ApcMin/+ mice

Altered Interactions between the Gut Microbiome and Colonic Mucosa Precede Polyposis in APCMin/+ Mice

PRMT5 Acts As a Tumor Suppressor by Inhibiting Wnt/β-catenin Signaling in Murine Gastric Tumorigenesis

PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression

Direct Transcriptional Functions Of The Apc Tumor Suppressor In Regulating Gene Expression

PRMT5 Deficiency Enforces the Transcriptional and Epigenetic Programs of Klrg1+CD8+ Terminal Effector T Cells and Promotes Cancer Development

Alteration Of Gene Expression In Normal-Appearing Colon Mucosa Of Apc(Min) Mice And Human Cancer Patients

Psmc5 Promotes Proliferation And Metastasis Of Colorectal Cancer By Activating Epithelial-Mesenchymal Transition Signaling And Modulating Immune Infiltrating Cells

Epimorphin deletion inhibits polyposis in the Apcmin/+ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion.

PO-192 the EMT Factor Zeb1 Promotes Adenoma Formation Through the Inhibition of Cell Senescence and Apoptosis

Abstract 6007: p16 epimutation modulates the tumor microenvironment and promotes malignancy of Apc -mutant colon cancer

Abstract A21: Direct transcriptional functions of the APC tumor suppressor in regulating gene expression

GPRC5A Deficiency Leads to Dysregulated MDM2 Via Activated EGFR Signaling for Lung Tumor Development